Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis

Journal of Rheumatology

Volumn 41, Issue 9, 2014, Pages 1843-1848

  Van Denderen, J Christiaan ^a   Visman, Ingrid M ^a   Nurmohamed, Michael T ^a,b   Suttorp Schulten, Maria S A ^c   Van Der Horst Bruinsma, Irene E ^b  

^a Jan Van Breemen Research Institute/Reade   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Department of Ophthalmology Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

Author keywords

ADALIMUMAB; ANKYLOSING; SPONDYLITIS; UVEITIS

Indexed keywords

ADALIMUMAB; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ADULT; ANKYLOSING SPONDYLITIS; COMPLICATION; FEMALE; HUMAN; MALE; MIDDLE AGED; RECURRENT DISEASE; TREATMENT OUTCOME; UVEITIS, ANTERIOR;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; UVEITIS, ANTERIOR;

EID: 84906877958     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.131289     Document Type: Article

References (32)

1. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial. Lancet 2002;359:1187-93. (Pubitemid 34304258)
2. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349-56. (Pubitemid 34754607)
3. Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BAC, Braun J, et al ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46. (Pubitemid 44051069)
4. Inman RD, Davis JC Jr, van der Heijde D, Diekman L, Sieper J, Kim SI, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008; 58:3402-12.
5. Linssen A, Rothova A, Valkenburg HA, Dekker-Saeys AJ, Luyendijk L, Kijlstra A, et al. The lifetime cumulative incidence of acute anterior uveitis in a normal population and its relation to ankylosing spondylitis and histocompatibility antigen HLA-B27. Invest Ophthalmol Vis Sci 1991;32:2568-78.
6. Wakefield D, Dunlop I, McCluskey PJ, Penny R. Uveitis: Aetiology and disease associations in an Australian population. Aust NZ J Ophthalmol 1986;14:181-7. (Pubitemid 17212136)
7. Zeboulon M, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: A systemic literature review. Ann Rheum Dis 2008;67:955-9. (Pubitemid 351956657)
8. Pato E, Bañares A, Jover JA, Fernández-Gutiérrez B, Godoy F, Morado C, et al. Undiagnosed spondyloarthropathy in patients presenting with anterior uveitis. J Rheumatol 2000;27:2198-202.
9. Linder R, Hoffmann A, Brunner R. Prevalence of the spondyloarthritides in patients with uveitis. J Rheumatol 2004;31:2226-9. (Pubitemid 39453243)
10. Monnet D, Breban M, Hudry C, Dougados M, Brézin AP. Ophthalmic findings and frequency of extraocular manifestations in patients with HLA-B27 uveitis: A study of 175 cases. Ophthalmology 2004;111:802-9. (Pubitemid 38429680)
11. Gensler L. Clinical features of ankylosing spondylitis. In: Hochberg MC, Silman AJ, Smolen JS, et al, editors. Rheumatology. Philadelphia: Mosby; 2011.
12. El-Shabrawi Y, Hermann J. Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 2002;109:2342-6. (Pubitemid 35417121)
13. Kruithof E, Kestelyn P, Elewaut C, Elewaut D, van den Bosch F, Mielants H, et al. Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis. Ann Rheum Dis 2002;61:470. (Pubitemid 34496831)
14. Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 2004;111:352-6. (Pubitemid 38183244)
15. Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, et al. A prospective trial of infliximab therapy for refractory uveitis. Arch Ophthalmol 2005;123:903-12.
16. Foster CS, Tufail F, Waheed NK, Chu D, Miserocchi E, Baltatzis S, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003;121:437-40. (Pubitemid 36427629)
17. Reddy AR, Backhouse OC. Does etanercept induce uveitis? Br J Ophthalmol 2003;87:925.
18. Rosenbaum JT. Effect of etanercept on iritis in patients with ankylosing spondylitis. Arthritis Rheum 2004;50:3736-7. (Pubitemid 39488709)
19. Guignard S, Gossec L, Salliot C, Ruyssen-Witrand A, Luc M, Duclos M, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: A retrospective study. Ann Rheum Dis 2006;65:1631-4. (Pubitemid 44799677)
20. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8. (Pubitemid 14134775)
21. Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, et al; for the ASAS Working Group. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003; 62:817-24. (Pubitemid 37026490)
22. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-16. (Pubitemid 41224845)
23. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
24. Garrett S, Henkinson T, Kennedy G, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
25. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garret SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS), the Bath AS Metrology Index. J Rheumatol 1994;21:1694-8. (Pubitemid 24285485)
26. Jones SD, Steiner A, Garrett SL, Calin A. The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Br J Rheumatol 1996;35:66-71.
27. Van der Heijde D, Calin A, Dougados M, Khan MA, van der Linden S, Bellamy N, on behalf of the ASAS Working Group. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. J Rheumatol 1999;26:951-4. (Pubitemid 29195692)
28. Sieper J, Koenig A, Baumgartner S, Wishneski C, Foehl J, Vlahos B, et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis trials. Ann Rheum Dis 2010;69:226-9.
29. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52:2447-51. (Pubitemid 41117431)
30. Rudwaleit M, Rødevand E, Holck P, Vanhoof J, Kron M, Kary S, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: Results of a prospective open-label study. Ann Rheum Dis 2009;68:696-701.
31. Tiliakos AN, Tiliakos NA. Ocular inflammatory disease in patients with RA taking etanercept: Is discontinuation of etanercept necessary? J Rheumatol 2003;30:2727. (Pubitemid 37549362)
32. Wendling D, Paccou J, Berthelot JM, Flipo RM, Guillaume-Czitrom S, Prati C, et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum 2011;41:503-10.